Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects With Active Crohn's Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study

Next Previous
X
Search
Trial Profile

An Open Label Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects With Active Crohn's Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Feb 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clarithromycin/clofazimine/rifabutin (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms MAPUS2
  • Sponsors RedHill Biopharma

    • Most Recent Events

    • 26 Feb 2020 This trial has been discontinued in Slovakia,according to European Clinical Trials Database record.
    • 11 Oct 2019 According to a RedHill Biopharma media release, a total of 54 subjects entered the open-label extension study and 30 subjects completed 52 weeks of treatment.
    • 11 Oct 2019 Interim Results presented in a RedHill Biopharma Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top